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Abstract
Objectives: It is unknown if telbivudine causes muscle damage only in patients with pre-existing muscle
pathology.
Case report: A 27 yo male of African origin received telbivudine for hepatitis B during 3 months. Three weeks
after initiation of the drug he developed myalgia, and tiredness. Creatine-kinase increased from 278 U/l (n, <170 U/
l) at baseline to 3243 U/l. Shortly after discontinuation of telbivudine muscle symptoms and hyper-CK-emia
disappeared. The findings suggest that pre-existing muscle damage favored the myotoxic effect of telbivudine.
Conclusions: Telbivudine appears to cause accelerated muscle toxicity if given to patients who already have
muscle damage. Patients under telbivudine should be closely monitored for muscular side effects and those with
pre-existing muscle damage should not receive the drug.
Introduction
Telbivudine has been reported to cause moderate hyper-
CK-emia in 9-12% of the treated patients [1,2]. The fol-
lowing case is important because it indicates that hyper-
CK-emia from telbivudine occurs predominantly in
patients with pre-existing subclinical muscle damage.
Case report
The patient is a 27 yo HIV-negative male of African ori-
gin with a language barrier and a history of inactive
hepatitis C, right-sided omalgia, a single episode of a
polymorphic psychosis at age 26 y, mild chronic renal
insufficiency (creatinine: 1.2 mg/dl (n, <1.1.mg/dl)) at
least since age 25 y, mild recurrent hyper-CK-emia, leu-
copenia, and thrombopenia, recurrent abdominal pain
presumably from chronic pancreatitis, and hyper-gam-
maglobulinemia (table 1). His family history was nega-
tive for neuromuscular disorder.
At age 24 y hepatitis B was diagnosed. The patient
received various antiviral therapies, such as lamivudine,
adefovir dipivoxil, and fenofovir always for a short time
because of low compliance, but effectively reducing the
v i r u sl o a da sl o n ga sh ea g r e e dt ot a k et h ed r u g .I n
April 2009 a therapy with telbivudine was started
without performing a pre-treatment resistance test.
Three weeks after initiation of telbivudine the patient
experienced myalgias and tiredness. Although creatine-
kinase (CK) had been elevated at least since age 25 y, it
further increased 10-15 fold since initiation of telbivu-
dine (table 1) why it was discontinued in June 2009. In
addition to the muscle problems he developed leucope-
nia, which had been occasionally observed already pre-
viously (table 1). Glutamate-oxalate transaminase,
glutamate-pyruvate transaminase, gamma-glutamyl
transpeptidase, alpha-amylase, and lipase remained
mildly elevated and the thrombocyte count and the glo-
merular filtration rate mildly declined before, during,
and after telbivudine treatment (table 1). HBsAg,
HBcAb, HBc-IgM-ab, and HBeAg were positive. Tropo-
nin-T was always normal and serum lactate at rest as
well. Clinical neurologic examination eleven days after
discontinuation of telbivudine revealed generally
reduced tendon reflexes exclusively. Whether reduced
tendon reflexes were due to neuropathy or myopathy
remains speculative since the patient refused to undergo
nerve conduction studies and electromyography.
Discussion
Telbivudine is a L-nucleoside analogue used for the
treatment of chronic hepatitis-B in adult patients with
compensated hepatopathy and indication of ongoing
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therapy should be continued at least until the HBeAg or
HBV-DNA become negative and the anti-HBe becomes
positive, until HBs seronegativity, or if the agent is inef-
fective. Like all other nucleoside analogues, telbivudine
inhibits polymerase gamma (POLG1), which is responsi-
ble for mtDNA replication [1]. Depletion of mtDNA is
associated with mitochondrial disease, including myopa-
thy and lactacidosis [1].
Hyper-CK-emia and myalgia have been repeatedly
reported in patients under telbivudine [4-6]. In a study
on 105 patients treated with telbivudine the main adverse
reactions were myalgia and general weakness [4]. In a
study on 1370 patients with hepatitis B asymptomatic
hyper-CK-emia was more common in patients receiving
telbivudine than lamivudine [5]. According to the
GLOBE-study telbivudine was associated with asympto-
matic hyper-CK-emia more frequently than lamivudine
(12.9 vs. 4.1%) [6]. In a Chocrane review (worldwide net
of scientists and physicians, which aims at providing sys-
tematic reviews about the assessment of medical treat-
ments) fatigue and malaise were found in 12-14% of the
cases, asymptomatic hyper-CK-emia in 9%, and definite
myopathy in 0.5% of the patients taking telbivudine [2].
In the instruction leaflet the manufacturer mentions
that telbivudine-induced muscle disease may develop
weeks or months after starting the therapy. Contrary to
this statement the presented patient developed muscle
symptoms and hyper-CK-emia already three weeks after
initiation of the drug. The rapid development of the
CK-increase may be due to the pre-existing muscle
damage. Pre-existing mild hyper-CK-emia may be attri-
butable either to nucleoside-analogue therapy prior to
telbivudine or to subclinical primary myopathy. Argu-
ments for a pre-existing primary myopathy are the gen-
erally reduced tendon reflexes, the elevated CK, GOT,
and GPT, the chronic pancreatitis, the psychotic
episode, and the renal insufficiency, although it cannot
be excluded that these abnormalities were due to pre-
vious anti-viral therapy or other causes.
Whether a patient with pre-existing muscle pathology
more frequently develops hyper-CK-emia or drug-
induced myopathy from telbivudine remains speculative,
but the presented case suggests such a pathomechanism.
Arguments for aggravation of pre-existing hyper-CK-
emia by telbivudine are that muscle symptoms and CK-
elevation started shortly after initiation of the drug and
that CK promptly and markedly declined after disconti-
nuation of the drug. Since muscle symptoms and hyper-
CK-emia resolved shortly after discontinuation of telbi-
vudine no muscle biopsy was initiated and the com-
plaints attributed to the therapy with telbivudine. In
patients with a language barrier it should be guaranteed
that the patient receiving drugs with potential side
effects is regularly asked for such side effects in his lan-
g u a g ea n dm o n i t o r e db ya p p r o p r i a t el a b o r a t o r yi n v e s t i -
gations recognized by the treating physician.
Conclusion
This case shows that telbivudine may accelerate muscle
damage if there is pre-existing muscle damage. Patients
under telbivudine should be closely monitored for mus-
cular side effects and those with pre-existing muscle
damage should not receive the drug.
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Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
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Table 1 Blood chemical values before, during (April to June 2009) and after telbivudine treatment in the described
patient
Parameter Reference value 1.6.07 1.6.07 241208 25.1208 19.3.09 8.4.09 3.7.09 6.7.09 7.7.09 9.7.09 10.7.09 21.7.09
Leucocytes 4.0-9.0/nl 4.6 5.4 5.2 5.1 3 3.3 3.6 3.6 3.2 nd 2.7 3.3
Thrombocytes 150-450/nl 129 153 108 119 127 119 121 124 122 nd 112 119
Creatine-kinase -170 U/l 212 nd 159 278 nd nd 3243 2816 2034 2352 2202 1210
GOT -34 U/l 144 377 40 40 nd nd nd 163 121 nd nd 71
GPT -44 U/l 118 375 57 60 nd nd nd 89 69 nd nd 51
GGT -54 U/l 147 278 63 69 nd nd nd 48 40 nd nd 36
Creatinine -1.1 mg/dl 1.2 1.1 1.43 1.13 1.5 1.4 1.23 1.13 1.2 1.3 1.3 1.13
GFR >90 ml/min/1.73 nd nd 64 83 60 65 75 83 77 70 70 83
Alpha-amylase 28-100 U/l 112 97 121 124 nd nd 127 118 125 nd nd 124
Lipase 13-60 U/l 77 53 72 55 nd nd nd nd 80 nd nd nd
Gamma-globulins 10-19% nd nd nd nd 20.7 19.9 nd nd 20.3 nd nd nd
GOT: glutamate-oxalate transaminase, GPT: glutamate-pyruvate transaminase, GGT: gamma-glutamyl-transpeptidase, GFR: glomerular filtration rate, Nd: not done
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